The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma
Abstract
BACKGROUND: The presence of hepatitis B e antigen (HBeAg) in serum indicates active viral replication in hepatocytes. HBeAg is thus a surrogate marker for the presence of hepatitis B virus DNA. We conducted a prospective study to determine the relation between positivity for hepatitis B surface antigen (HBsAg) and HBeAg and the development of hepatocellular carcinoma. METHODS: In 1991 and 1992, we enrolled 11,893 men without evidence of hepatocellular carcinoma (age range, 30 to 65 years) from seven townships in Taiwan. Serum samples obtained at the time of enrollment were tested for HBsAg and HBeAg by radioimmunoassay. The diagnosis of hepatocellular carcinoma was ascertained through data linkage with the computerized National Cancer Registry in Taiwan and with death certificates. We performed a multiple regression analysis to determine the relative risk of hepatocellular carcinoma among men who were positive for HBsAg alone or for HBsAg and HBeAg, as compared with those who were negative for both. RESULTS: There were 111 cases of newly diagnosed hepatocellular carcinoma during 92,359 person-years of follow-up. The incidence rate of hepatocellular carcinoma was 1169 cases per 100,000 person-years among men who were positive for both HBsAg and HBeAg, 324 per 100,000 person-years for those who were positive for HBsAg only, and 39 per 100,000 person-years for those who were negative for both. After adjustment for age, sex, the presence or absence of antibodies against hepatitis C virus, cigarette-smoking status, and use or nonuse of alcohol, the relative risk of hepatocellular carcinoma was 9.6 (95 percent confidence interval, 6.0 to 15.2) among men who were positive for HBsAg alone and 60.2 (95 percent confidence interval, 35.5 to 102.1) among those who were positive for both HBsAg and HBeAg, as compared with men who were negative for both. CONCLUSIONS: Positivity for HBeAg is associated with an increased risk of hepatocellular carcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biology of disease: free radicals and tissue injury.
Freeman, B. Α., & Jd, C. (1982) · PubMed · Cited by 3,038
IARC monographs on the evaluation of carcinogenic risks to humans
Hopkins, J. (1989) · Food and Chemical Toxicology · doi:10.1016/0278-6915(89)90054-9 · Cited by 2,876
HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS
Beasley, R. P., Lin, C.-C., Hwang, L.-Y., & Chien, C.-S. (1981) · The Lancet · doi:10.1016/s0140-6736(81)90585-7 · Cited by 2,865
Wang, J. C. (1985) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.54.070185.003313 · Cited by 1,540
Nonparametric Inference for a Family of Counting Processes
Aalen, O. (1978) · The Annals of Statistics · doi:10.1214/aos/1176344247 · Cited by 1,483
HBx gene of hepatitis B virus induces liver cancer in transgenic mice
Kim, C.-M., Koike, K., Saito, I., Miyamura, T., & Jay, G. (1991) · Nature · doi:10.1038/351317a0 · Cited by 1,158
Long-Term Follow-up of HBeAg-Positive Patients Treated with Interferon Alfa for Chronic Hepatitis B
Niederau, C., Heintges, T., Lange, S., Goldmann, G., Niederau, C. M., Mohr, L., & Häussinger, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199605303342202 · Cited by 803
A Large Sample Study of the Life Table and Product Limit Estimates Under Random Censorship
Breslow, N., & Crowley, J. (1974) · The Annals of Statistics · doi:10.1214/aos/1176342705 · Cited by 728
Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice
Chisari, F. V., Klopchin, K., Moriyama, T., Pasquinelli, C., Dunsford, H. A., Sell, S., Pinkert, C. A., Brinster, R. L., & Palmiter, R. D. (1989) · Cell · doi:10.1016/0092-8674(89)90770-8 · Cited by 697
Epidemiological characteristics and risk factors of hepatocellular carcinoma
CHEN, C., YU, M., & LIAW, Y. (1997) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.1997.tb00513.x · Cited by 470
Self-citationLin, S.-M., Sheen, I.-S., Chien, R.-N., Chu, C.-M., & Liaw, Y.-F. (1999) · Hepatology · doi:10.1002/hep.510290312 · Cited by 444
Self-citationFrom Hepatitis to Hepatoma: Lessons from Type B Viral Hepatitis
Chen, D.-S. (1993) · Science · doi:10.1126/science.8211155 · Cited by 325
Self-citationAbrogation of p53-Induced Apoptosis by the Hepatitis B Virus X Gene
Wang, X. W. (2003) · Hepatocellular Carcinoma · doi:10.1385/1-59259-079-9:57 · Cited by 321
Feitelson, M. A., Zhu, M., Duan, L., & London, W. T. (1993) · PubMed · Cited by 307
Hepatocarcinogenicity of the woodchuck hepatitis virus.
Popper, H., Roth, L., Purcell, R. H., Tennant, B. C., & Gerin, J. L. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.3.866 · Cited by 269
Paterlini, P., Poussin, K., Kew, M., Franco, D., & Brechot, C. (1995) · Hepatology · doi:10.1002/hep.1840210208 · Cited by 249
Chen, C.-J., Liang, K.-Y., Chang, A.-S., Chang, Y.-C., Lu, S.-N., Liaw, Y.-F., Chang, W.-Y., Sheen, M.-C., & Lin, T.-M. (1991) · Hepatology · doi:10.1002/hep.1840130303 · Cited by 247
Self-citationIdentification of integrated hepatitis B virus DNA sequences in human hepatocellular carcinomas
Shafritz, D. A., & Kew, M. C. (1981) · Hepatology · doi:10.1002/hep.1840010102 · Cited by 216
Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis.
Matsubara, K., & Tokino, T. (1990) · PubMed · Cited by 161
Association between hepatitis C virus antibodies and hepatocellular carcinoma in Taiwan.
Yu, M., You, S., Chang, A. S., Lu, S.-N., Liaw, Y., & Chen, C. (1991) · PubMed · Cited by 136
Self-citationA case-control study of primary hepatocellular carcinoma in Taiwan
Lu, S., Lin, T., Chen, C., Chen, J. S., Liaw, Y., Chang, W., & Hsu, S. T. (1988) · Cancer · doi:10.1002/1097-0142(19881101)62:9<2051::aid-cncr2820620930>3.0.co;2-1 · Cited by 110
Self-citationTsai, J.-F., Jeng, J., Ho, M., Chang, W., Hsieh, M., Lin, Z., & Tsai, J. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.283 · Cited by 49
Hepatitis viruses and hepatocellular carcinoma
Kew, M. C. (1998) · Research in Virology · doi:10.1016/s0923-2516(99)89003-7 · Cited by 34
Small sample and efficiency results for the Nelson-Aalen estimator
Peña, E. A., & Rohatgi, V. K. (1993) · Journal of Statistical Planning and Inference · doi:10.1016/0378-3758(93)90088-n · Cited by 15
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
Marrero, J. A., Kulik, L. M., Sirlin, C. B., Zhu, A. X., Finn, R. S., Abecassis, M. M., Roberts, L. R., & Heimbach, J. K. (2018) · Hepatology · doi:10.1002/hep.29913 · Cited by 4,539
Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
El-Serag, H. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.061 · Cited by 3,380
Metadata
- Authors
- Yang, H.-I., Lu, S.-N., Liaw, Y.-F., You, S.-L., Sun, C.-A., Wang, L.-Y., Hsiao, C. K., Chen, P.-J., Chen, D.-S., & Chen, C.-J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-07-18
- Volume
- 347
- Issue
- 3
- Pages
- 168-174
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2314866596
- Cited by
- 1,222
- References
- 24
- FWCI
- 37.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.